IG-SRT Commercial Deployment
Non-Melanoma Skin Cancer (Basal Cell Carcinoma, Squamous Cell Carcinoma)
CommercialActive
Key Facts
Indication
Non-Melanoma Skin Cancer (Basal Cell Carcinoma, Squamous Cell Carcinoma)
Phase
Commercial
Status
Active
Company
About SkinCure Oncology
SkinCure Oncology, founded in 2017, commercializes Image-Guided Superficial Radiation Therapy (IG-SRT) as a patient-friendly, non-surgical treatment for non-melanoma skin cancers like basal cell and squamous cell carcinoma. The company operates a partnership-based business model, equipping and supporting dermatology practices across the US to offer this technology, thereby expanding patient access to an effective alternative with a reported 99%+ cure rate and high patient satisfaction. As of early 2026, SkinCure Oncology reports treating over 140,000 patients across more than 380 partner practices in 48 states, indicating rapid commercial adoption and scale.
View full company profile